Publications

• New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma

  Maggie Banys-Paluchowski

  PMID: 10.1055/a-1850-9512 Show Details link to full text
  Study

  Year

  2023

  Keywords

  • HER2
  • breast cancer

• Breast Cancer and Genetic BRCA1/2 Testing in Routine Clinical Practice: Why, When and For Whom?

  Michael P. Lux, Peter A. Fasching

  PMID: 10.1055/a-1929-2629 Show Details link to full text
  Study

  Year

  2023

  Keywords

  • breast cancer

• Incidental Pulmonary Nodules - What Do We Know in 2022

  Gerald Schmid-Bindert, Jens Vogel-Claussen, Sylvia Gütz, Joana Fink, Hans Hoffmann, Martin E. Eichhorn, Felix J.F. Herth

  PMID: 36228594 Show Details link to full text
  Study

  Year

  2022

  Keywords

  • lung cancer

• A Prospective Study to Evaluate the Impact of Golimumab Therapy on Work Productivity and Activity, and Quality of Life in Patients with Rheumatoid Arthritis, Psoriasis Arthritis and Axial Spondyloarthritis in a Real Life Setting in AUSTRIA. The GO-ACTIVE

  C. Dejaco, T. Mueller, O. Zamani, U. Kurtz, S. Egger, J. Resch-Passini, A. Totzauer, B. Yazdani-Biuki, T. Schwingenschloegl, P. Peichl, A. Kraus, G. W. Naerr

  PMID: 35721062 Show Details link to full text
  Study

  GO ACTIVE

  Year

  2022

  Keywords

  • rheumatoid arthritis
  • psoriatic arthritis
  • axial spondyloarthritis
  • golimumab
  • QoL
  • WPAI

• Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program.

  V. Müller, M. Banys-Paluchowski, T.W.P. Friedl, P.A. Fasching, A. Schneeweiss, A. Hartkopf, D. Wallwiener, B. Rack, F. Meier-Stiegen, J. Huober, M. Rübner, O. Hoffmann, L. Müller, W. Janni, P. Wimberger, B. Jäger, K. Pantel, S. Riethdorf, N. Harbeck, T. Fehm, DETECT study group

  PMID: 34839105 Show Details link to full text
  Study

  DETECT

  Year

  2021

  Keywords

  • breast cancer
  • liquid biopsy
  • HER2
  • oncology

• Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 months.

  N. Teich, H. Grümmer, E. Jörgensen, T. Liceni, F. Holtkamp-Endemann, T. Fischer, S. Hohenberger

  PMID: 33845784 Show Details link to full text
  Study

  Go CUTE II

  Year

  2021

  Keywords

  • golimumab
  • ulcerative colitis
  • QoL
  • WPAI
  • HCRU

• Effect of Originator Infliximab Treatment on Disease-Related Hospitalizations, Work Productivity and Activity Impairment, and Health Resource Utilization in Patients with Crohn's Disease in a Real-Life Setting: Results of a Prospective Multicenter Study i

  N. Teich, M. Bläker, F. Holtkamp-Endemann, E. Jörgensen, A. Stallmach, S. Hohenberger

  PMID: 33850839 Show Details link to full text
  Study

  MC Productive

  Year

  2021

  Keywords

  • Crohn's disease
  • infliximab
  • QoL
  • WPAI
  • HRQoL

• Neoadjuvant and adjuvant end-points in health technology assessment in oncology.

  N. Harbeck, A. Schneeweiss, P. Thuss-Patience, K. Miller, C. Garbe, F. Griesinger, W. E. E. Eberhardt, J. P. Klussmann, B. Wollenberg, M. O. Grimm, T. Zander, D. Lüftner

  PMID: 33611103 Show Details link to full text
  Study

  AMNOG

  Year

  2021

  Keywords

  • immunotherapy
  • oncology

• Switching COPD patients from the disposable to the new reusable Respimat soft mist inhaler: a real-world study from Switzerland

  A. Tschacher, C. Cadus, S. Schildge, J. P. Diedrich, P. N. Chhajed, A. B. Leuppi-Taegtmeyer, J. D. Leuppi

  PMID: 34433362 Show Details link to full text
  Study

  NTA Switch

  Year

  2021

  Keywords

  • Respimat inhaler
  • COPD

• Klinisches Managment von PARP-Inhibitoren

  B. Schmalfeldt

  PMID: Show Details link to full text
  Study

  Year

  2021

  Keywords

  • PARP inhibitors
  • ovarian cancer
  • oncology